Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

RYOJ vs NSRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NSRX Captures Overall Composite Edge (45.4 HOLD vs 42.9 HOLD), While RYOJ Leads 5–0 on Growth & Valuation Pillars

NSRX Overall Winner 6-Pillar Tally: RYOJ 5 – 0 NSRX (1 Tie) Matrix Metrics: RYOJ 3 – 4 NSRX

As of Nov 19, 2026, Nasus Pharma Ltd. (NSRX) captures the overall head-to-head institutional edge over rYojbaba Co., Ltd. Common Shares (RYOJ) on higher Unified Composite conviction (45.4/100 HOLD vs. 42.9/100 HOLD) after splitting the core matrix 4–3 (led by composite factor balance), while RYOJ wins 5–0 across the 6-pillar growth and valuation breakdown. RYOJ trades at $2.23 (N/M Forward P/E, -8.1% operating margin) versus NSRX at $2.55 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: NSRX earns the overall head-to-head edge with a stronger Unified Composite Score (45.4/100 HOLD vs. RYOJ 42.9/100 HOLD) and 1.00β · 69% Vol risk profile, whereas RYOJ leads top-line expansion (-34.3% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: RYOJ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.3); meanwhile NSRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RYOJ vs NSRX
RYOJ NASDAQ
rYojbaba Co., Ltd. Common Shares
Services-Management Consulting Services
$2.23
-0.89% 1D
Market Cap $26.0M
TTM Revenue $9.3M
Forward P/E N/M
Beta / 30D Vol 1.68β · 92% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 23.0 Fund 50.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -26.4%), weak momentum, RSI 37
RSI-14: 37.3 · SMA20: $2.45 · SMA50: $2.95
NSRX NYSE American Head-to-Head Winner
Nasus Pharma Ltd.
Pharmaceutical Preparations
$2.55
-5.56% 1D
Market Cap $31.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.00β · 69% Vol
Unified Composite Score
45.4 / 100 HOLD
Tech 33.0 Fund 54.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.0%), weak momentum, RSI 33
RSI-14: 32.5 · SMA20: $3.00 · SMA50: $3.29

6-Pillar Scorecard Institutional Category Breakdown (RYOJ 5 – 0 NSRX)

Columns: Metric · RYOJ · NSRX
1. Valuation Multiples RYOJ
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 2.8x N/M
2. Growth & Scale RYOJ
Revenue Growth (YoY) -34.3% +0.0%
Earnings Growth (YoY) +11.8% +0.0%
TTM Revenue (USD) $9.3M N/A
Market Cap $26.0M $31.6M
3. Profitability & Quality RYOJ
Gross Margin 26.6% N/A
Operating Margin -8.1% 0.0%
Net Profit Margin 1.3% 0.0%
Return on Equity (ROE) 2.8% -316.0%
4. Balance Sheet & Cash Flow RYOJ
Cash Generation (TTM) -$59,921 EBITDA N/A
Cash Flow Margin -0.6% EBITDA Mgn N/A
Net Cash / Leverage $0.53 Book/Sh · 2.8% ROE $0.94 Book/Sh · -316.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat RYOJ
OpEx & R&D Intensity 34.7% of Rev ($3.2M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Consulting Services Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RYOJ (3) vs NSRX (4)
Institutional Metric RYOJ NSRX Criterion Row Edge
Market Capitalization
Scale
$26.0M $31.6M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-34.3% +0.0% Higher Growth NSRX
Operating Margin (TTM)
Profitability
-8.1% 0.0% Higher Margin NSRX
Net Profit Margin
Profitability
1.3% 0.0% Higher Margin RYOJ
Return on Equity (ROE)
Capital Efficiency
2.8% -316.0% Higher ROE RYOJ
52-Week Range Position
Momentum
10% ($2–$8) 8% ($2–$10) Stronger Trend RYOJ
Beta / 30D Volatility
Risk Regime
1.68β · 92% Vol 1.00β · 69% Vol Lower Realized Risk NSRX
Unified Institutional Score
Composite Signal
42.9 / 100 (HOLD) 45.4 / 100 (HOLD) Higher Composite NSRX
Trailing 12M Revenue (USD)
Operating Scale
$9.3M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
26.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$59,921 EBITDA ($0.53 Book/Sh · 2.8% ROE) N/A ($0.94 Book/Sh · -316.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RYOJ +5.16 pp
RYOJ: -11.51% · NSRX: -16.67%
3M Horizon NSRX +18.89 pp
RYOJ: -52.66% · NSRX: -33.77%
6M Horizon RYOJ +20.7 pp
RYOJ: +13.77% · NSRX: -6.93%
1Y Horizon RYOJ +17.43 pp
RYOJ: -48.97% · NSRX: -66.4%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RYOJ vs NSRX. Trailing 12-month operating profitability (RYOJ -8.1% vs NSRX 0.0%) and valuation multiples (RYOJ N/M vs NSRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

RYOJ ADR TTM Benchmark FX-Normalized USD
TTM Revenue$9.3M
Gross Margin26.6%
Op. Margin-8.1%
ROE / Fwd P/E2.8% · N/M
NSRX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-316.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RYOJ UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RYOJ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NSRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NSRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RYOJ Moat Profile Cyclical / Execution-Driven Positioning
Consulting Services Operator
Competes within the Consulting Services value chain with $26.0M market capitalization and -8.1% operating margin.
OpEx & R&D Reinvestment 34.7% of Rev ($3.2M)
90D Engineering Disclosures 0 Published
NSRX Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $31.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RYOJ vs NSRX Key Questions & Quantitative Answers

As of Nov 19, 2026, Nasus Pharma Ltd. (NSRX) captures the overall head-to-head institutional edge over rYojbaba Co., Ltd. Common Shares (RYOJ) on higher Unified Composite conviction (45.4/100 HOLD vs. 42.9/100 HOLD) after splitting the core matrix 4–3 (led by composite factor balance), while RYOJ wins 5–0 across the 6-pillar growth and valuation breakdown. RYOJ trades at $2.23 (N/M Forward P/E, -8.1% operating margin) versus NSRX at $2.55 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: NSRX earns the overall head-to-head edge with a stronger Unified Composite Score (45.4/100 HOLD vs. RYOJ 42.9/100 HOLD) and 1.00β · 69% Vol risk profile, whereas RYOJ leads top-line expansion (-34.3% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: RYOJ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.3); meanwhile NSRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RYOJ leads the Growth & Scale pillar: RYOJ posts -34.3% YoY revenue growth and +11.8% YoY earnings growth on $9.3M TTM revenue (26.6% gross margin, -8.1% operating margin), compared with NSRX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, RYOJ generates $9.3M in USD-normalized revenue versus N/A for NSRX. In operating R&D and SG&A reinvestment, RYOJ deploys 34.7% of Rev ($3.2M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NSRX.

RYOJ screens cheaper on headline valuation multiples. RYOJ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.8x EV/Revenue (-0.6% EBITDA margin), whereas NSRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RYOJ (2.8% ROE) versus NSRX (-316.0% ROE) capital efficiency.

In options market volatility and institutional positioning, RYOJ carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.68β · 92% Vol realized risk). By comparison, NSRX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.00β · 69% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.